profit from every £100 of sales.
£0£100
Johnson Matthey
£23.88-0.75% today
+12.0% in 1 year
1-year low £17.881-year high £29.49
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Johnson Matthey sold, what it kept, and what it did with the cash.
Sales went from £14.9 billion in 2023 to £12.6 billion in 2026, with -£96.0 million of profit last year.
SalesProfit
Johnson Matthey handed back 57% of the cash it generated last year.
£129M
Free cash flow 2026£226M
Bought back its own shares£0
Paid as dividends£129M
Cash vs. debt£536M vs. £1.4B
Johnson Matthey vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from £100 of sales | Sales growth a year | Price per £1 of profit |
|---|---|---|---|
| Johnson Matthey | No profit yet | ||
 Linde | 35.0× · Expensive | ||
 L'Air Liquide | 35.1× · Expensive | ||
 Ecolab | 41.8× · Expensive | ||
 The Sherwin-Williams | 32.9× · Expensive |
AI analysis
An AI analyst reads Johnson Matthey's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of GBP | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 14,933 | 12,843 | 11,022 | 12,573 | |
| 994 | 927 | 684 | 629 | |
| 460 | 406 | 299 | 340 | |
| 621 | 488 | 687 | 405 | |
| 276 | 108 | 373 | -96 | |
| 1.50 | 0.58 | 2.11 | -0.57 | |
| 6.7% | 7.2% | 6.2% | 5.0% | |
| 3.1% | 3.2% | 2.7% | 2.7% | |
| 1.8% | 0.8% | 3.4% | -0.8% |
Balance sheet
| In millions of GBP | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 7,029 | 6,336 | 6,194 | 5,974 |
| Cash | 650 | 542 | 898 | 536 |
| Total debt | 1,668 | 1,490 | 1,704 | 1,405 |
| Total liabilities | 4,490 | 3,956 | 3,899 | 3,958 |
| 2,539 | 2,380 | 2,295 | 2,016 | |
| 184 | 184 | 176 | 169 | |
| 7.7% | 5.7% | 10.0% | 5.6% | |
| 10.9% | 4.5% | 16.3% | -4.8% |
Cash flow
| In millions of GBP | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 291 | 592 | 381 | 465 | |
| 316 | 368 | 301 | 239 | |
| -25 | 224 | 80 | 226 | |
| Dividends paid | 141 | 141 | 138 | 129 |
| 45 | 0 | 251 | 0 | |
| 7 | 5 | 6 | 6 |
Valuation
- –
- –
- –
- 1.5×
- 0.2×
- 13.1×
- 9.4×
- 7.7%
- -3.3%
- 4.4%
Profitability
- 5.0%
- 2.7%
- -0.8%
- –
- 11.5%
- 7.7%
- –
- –
- –
- –
Growth
- −5.6%
- –
- –
- –
- −2.8%
Financial health
- 1.0×
- 0.74
- –
- 4.8×
- 1.42
- –
- –
How it ranks in Materials
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 25%of 989
Bottom 18%of 954
Bottom 22%of 940
Top 20%of 990
4.4%of the share price, paid each year
On $1,000 invested$44a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
: 57.1%
News
Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?Yahoo Finance · Nov 11, 2026Johnson & Johnson (JNJ): Limited Analyst Upside, but Management Sees a Clearer Path to GrowthYahoo Finance · Nov 8, 2026Johnson & Johnson reports 94% success rate in trial of coronary artery deviceSeeking Alpha · Nov 1, 2026Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors.Yahoo Finance · Oct 31, 2026Johnson & Johnson reports response rate for head, neck cancer treatmentSeeking Alpha · Oct 25, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
30No pass
Benjamin Graham
43No pass
Philip Fisher
31No pass
Peter Lynch
26No pass
Joel Greenblatt
30No pass
Charlie Munger
23No pass
Terry Smith
14No pass
Questions about Johnson Matthey
Is Johnson Matthey a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Johnson Matthey AI analysis
What does Johnson Matthey do?
Johnson Matthey Plc engages in the clean air, catalyst and hydrogen technology, and platinum group metals (PGM) service businesses in the United Kingdom, Germany, rest of Europe, the United States, rest of North America, China, rest of Asia, and internationally. It is in Specialty Chemicals, based in London, United Kingdom.
Does Johnson Matthey pay a dividend?
Yes. At today's price the dividend is 4.4% a year. In 2026 it paid out £129 million in dividends.
Is Johnson Matthey stock halal?
No. Johnson Matthey does not pass our halal screen: its debt is 48% of its market value, at or above the 33% limit. How we check
How has Johnson Matthey stock done over the past year?
Up 12.0% over the past twelve months, to £23.88. It traded between £17.88 and £29.49 and is 19.0% below its high.
Who are Johnson Matthey's competitors?
The largest listed companies in the same industry are Linde, L'Air Liquide, Ecolab and The Sherwin-Williams. The peers table on this page compares their profit, growth and price with Johnson Matthey's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.